1. A 64-year-old man underwent coronary stenting two weeks ago and takes aspirin plus clopidogrel, a prodrug that requires activation by CYP2C19 (cytochrome P450 2C19) to inhibit platelets. He now has frequent reflux symptoms and his cardiologist wants to add acid suppression while protecting his antiplatelet therapy. Which proton pump inhibitor is the most appropriate choice?
A) Omeprazole, because it is the most established agent
B) Pantoprazole, because it has minimal CYP2C19 inhibitory activity and is least likely to reduce clopidogrel's activation
C) Esomeprazole, because it is the S-enantiomer of omeprazole
D) High-dose omeprazole, because a higher dose overrides any interaction
E) Cimetidine, because an H2 receptor antagonist avoids all enzyme effects
ANSWER: B
Rationale:
This patient needs reliable clopidogrel activation, which depends on CYP2C19. A proton pump inhibitor that inhibits CYP2C19 can reduce conversion of clopidogrel to its active metabolite. Pantoprazole has minimal CYP2C19 inhibition and is therefore the preferred agent when a proton pump inhibitor is needed alongside clopidogrel and the patient is not at high gastrointestinal bleeding risk.
Option A: Option A is incorrect: omeprazole is a significant CYP2C19 inhibitor and is exactly the kind of agent to avoid here.
Option C: Option C is incorrect: esomeprazole also inhibits CYP2C19 and shares the interaction; being the S-enantiomer of omeprazole does not eliminate it.
Option D: Option D is incorrect: raising the omeprazole dose increases, rather than overrides, CYP2C19 inhibition.
Option E: Option E is incorrect: cimetidine is a notably broad CYP inhibitor and is the opposite of an enzyme-neutral choice.
2. A 48-year-old woman in a large U.S. city has a confirmed Helicobacter pylori-associated duodenal ulcer. She completed clarithromycin-based triple therapy for a respiratory infection last year and her local clarithromycin resistance rate exceeds 15 percent. Which first-line eradication regimen is most appropriate now?
A) Repeat the same clarithromycin triple therapy for 14 days
B) A proton pump inhibitor alone for 4 weeks
C) Clarithromycin triple therapy at a higher clarithromycin dose
D) Bismuth quadruple therapy (a proton pump inhibitor plus bismuth plus metronidazole plus tetracycline), which does not depend on clarithromycin and remains effective despite resistance or prior macrolide exposure
E) An H2 receptor antagonist combined with amoxicillin only
ANSWER: D
Rationale:
This patient has two strong reasons to avoid a clarithromycin-containing regimen: prior macrolide exposure and a local clarithromycin resistance rate above 15 percent, both of which predict failure of clarithromycin triple therapy. Bismuth quadruple therapy contains no clarithromycin and achieves high eradication rates regardless of clarithromycin resistance, making it the preferred first-line choice in this setting.
Option A: Option A is incorrect: repeating a regimen the organism is likely resistant to invites another failure.
Option B: Option B is incorrect: a proton pump inhibitor alone does not eradicate the infection.
Option C: Option C is incorrect: increasing the clarithromycin dose does not overcome 23S rRNA target-site resistance.
Option E: Option E is incorrect: a single antibiotic with an H2 receptor antagonist is not an adequate eradication regimen and promotes resistance.
3. A 71-year-old woman on a proton pump inhibitor for several years and on digoxin for atrial fibrillation presents with muscle cramps and fatigue. Serum magnesium is low. Despite a course of oral magnesium supplementation, the level does not improve. What is the most appropriate management?
A) Stop the proton pump inhibitor, because long-term acid suppression impairs intestinal magnesium absorption via the pH-dependent TRPM6 channel and oral magnesium cannot correct the deficit while the absorptive defect persists
B) Continue the proton pump inhibitor and simply increase the oral magnesium dose further
C) Attribute the low magnesium to diet and make no medication change
D) Stop the digoxin, since it is the cause of the hypomagnesemia
E) Add a second proton pump inhibitor to deepen acid suppression
ANSWER: A
Rationale:
This is classic proton pump inhibitor-induced hypomagnesemia. Intestinal magnesium absorption through the TRPM6 channel depends on luminal acidity, and long-term acid suppression impairs it. Because the defect is in absorption itself, oral magnesium is poorly absorbed and fails to correct the level — the proton pump inhibitor must be stopped. The danger is heightened by concurrent digoxin, where low magnesium potentiates toxicity and arrhythmia risk.
Option B: Option B is incorrect: more oral magnesium will not work while the absorptive defect persists.
Option C: Option C is incorrect: the temporal link to long-term proton pump inhibitor use and the failure of oral repletion point to the drug, not diet.
Option D: Option D is incorrect: digoxin does not cause hypomagnesemia; rather, hypomagnesemia worsens digoxin toxicity.
Option E: Option E is incorrect: adding more acid suppression would worsen the absorptive defect.
4. A 29-year-old woman with rheumatoid arthritis requires chronic NSAID (non-steroidal anti-inflammatory drug) therapy and needs gastroprotection. She is sexually active and not using reliable contraception, and a current pregnancy has not been excluded. Which gastroprotective strategy is most appropriate?
A) Misoprostol, because it is the most logical pharmacologic match for NSAID-induced injury
B) Misoprostol at a reduced dose, which is safe in early pregnancy
C) A proton pump inhibitor, because misoprostol is absolutely contraindicated when pregnancy cannot be excluded and reliable contraception is not in place
D) No gastroprotection is needed in a young patient
E) An antacid taken as needed in place of any preventive agent
ANSWER: C
Rationale:
Although misoprostol is a pharmacologically logical NSAID gastroprotective agent, it is a prostaglandin E1 analog that stimulates uterine contractions and is absolutely contraindicated in pregnancy (Pregnancy Category X), even at the gastroprotective dose. In a woman of childbearing potential without excluded pregnancy or reliable contraception, a proton pump inhibitor is the preferred gastroprotective agent.
Option A: Option A is incorrect: despite its mechanistic fit, misoprostol cannot be used here because of the pregnancy risk.
Option B: Option B is incorrect: there is no safe misoprostol dose in pregnancy; the contraindication is absolute, not dose-dependent.
Option D: Option D is incorrect: chronic NSAID therapy warrants gastroprotection regardless of youth.
Option E: Option E is incorrect: on-demand antacids do not provide reliable ulcer prophylaxis for a chronic NSAID user.
5. A 55-year-old man who took a proton pump inhibitor daily for two years stopped it abruptly on his own. Five days later he reports heartburn that is worse than anything he had before starting the drug. He is otherwise well, with no alarm features. What is the best explanation and management?
A) He has developed a perforated ulcer and needs emergency surgery
B) The proton pump inhibitor permanently damaged his stomach, so symptoms will be lifelong
C) He has a new Helicobacter pylori infection requiring antibiotics
D) The worsening proves he was never an appropriate candidate for acid suppression
E) This is rebound acid hypersecretion from hypergastrinemia-driven ECL (enterochromaffin-like) cell hyperplasia after long-term suppression; it is transient (1 to 2 weeks), and future discontinuation should use a gradual taper or step-down to an H2 receptor antagonist
ANSWER: E
Rationale:
The history — worse-than-baseline heartburn days after abrupt cessation of long-term therapy, with no alarm features — is characteristic of rebound acid hypersecretion. Chronic suppression raises gastrin and expands the ECL cell population; when the drug is suddenly removed, that apparatus drives a transient surge of acid lasting one to two weeks. The appropriate approach is reassurance plus a gradual taper or step-down to an H2 receptor antagonist when discontinuing.
Option A: Option A is incorrect: there are no features of perforation, which would present as an acute surgical abdomen.
Option B: Option B is incorrect: the change is reversible adaptive hypergastrinemia, not permanent damage.
Option C: Option C is incorrect: the picture fits rebound hypersecretion, not a new infection requiring antibiotics.
Option D: Option D is incorrect: the rebound is an expected withdrawal phenomenon, not evidence that therapy was inappropriate.
6. A 60-year-old man is mechanically ventilated in the ICU. The team wants stress ulcer prophylaxis but is specifically concerned about complications linked to raising intragastric pH, such as gastric bacterial overgrowth. His renal function is normal. Which agent's mechanism best fits this specific concern?
A) Omeprazole, because deep acid suppression is always the safest prophylaxis
B) Sucralfate, because it protects the mucosa by forming an adherent barrier without raising intragastric pH, which is associated in some trials with less ventilator-associated pneumonia than acid-suppressing agents
C) A high-dose intravenous proton pump inhibitor, because it most raises gastric pH
D) Calcium carbonate antacid around the clock
E) Cimetidine, because broad enzyme inhibition is protective in the ICU
ANSWER: B
Rationale:
The team's concern is specifically about the consequences of raising gastric pH. Sucralfate provides mucosal protection through an adherent physical barrier and stimulation of local defenses without meaningfully raising intragastric pH; because gastric acidity is preserved, bacterial overgrowth is less favored, and some trials have associated sucralfate with a lower incidence of ventilator-associated pneumonia than pH-raising agents. With normal renal function, aluminum accumulation is not a concern.
Option A: Option A is incorrect: deeper acid suppression is exactly what the team wishes to avoid given the pH-related concern.
Option C: Option C is incorrect: a high-dose intravenous proton pump inhibitor maximally raises pH, the opposite of what is wanted here.
Option D: Option D is incorrect: a calcium carbonate antacid both raises pH and is impractical for continuous prophylaxis.
Option E: Option E is incorrect: cimetidine raises pH and adds broad drug interactions without addressing the specific concern.
7. A 50-year-old woman with reflux is well controlled during the day on a correctly timed once-daily proton pump inhibitor taken before breakfast, but she continues to wake at night with acid symptoms. What is the most appropriate addition to her regimen, and why?
A) Switch her entirely to an antacid taken at night
B) Double the morning proton pump inhibitor and take it at bedtime instead
C) Add a second proton pump inhibitor dose at bedtime as the only effective option
D) Add a bedtime H2 receptor antagonist, because nocturnal acid secretion is largely histamine-driven and relatively meal-independent, the pathway an H2 receptor antagonist most effectively targets, making it a logical supplement for nocturnal acid breakthrough
E) Stop the proton pump inhibitor entirely and rely on famotidine alone
ANSWER: D
Rationale:
Nighttime acid secretion is predominantly histamine-driven and relatively independent of meals — exactly the pathway an H2 receptor antagonist blocks well. Because proton pump inhibitors act mainly on meal-recruited active pumps, some patients have nocturnal acid breakthrough despite good daytime control. Adding a bedtime H2 receptor antagonist targets the histamine-driven nighttime secretion and is an established supplement for this problem.
Option A: Option A is incorrect: an antacid gives only brief relief and does not address sustained nocturnal secretion.
Option B: Option B is incorrect: moving the proton pump inhibitor to bedtime would worsen daytime control because the morning meal-driven surge would no longer be covered.
Option C: Option C is incorrect: a bedtime proton pump inhibitor dose is less mechanistically suited to histamine-driven nocturnal secretion than a bedtime H2 receptor antagonist, which is the targeted choice here.
Option E: Option E is incorrect: stopping the proton pump inhibitor sacrifices the deeper daytime suppression she relies on.
8. A 45-year-old man with frequent reflux was started on famotidine for ongoing maintenance. It worked well initially, but after about two weeks of continuous daily use his symptom control has clearly diminished, despite good adherence and an unchanged dose. What is the best explanation and next step?
A) He has developed tachyphylaxis to the H2 receptor antagonist, an expected tolerance with continuous use; for sustained maintenance suppression, switch to a proton pump inhibitor, which acts irreversibly at the pump and does not show this degree of tolerance
B) He is non-adherent and needs no medication change
C) The famotidine has chemically degraded and a fresh prescription will restore the effect
D) He should triple the famotidine dose indefinitely to outpace tolerance
E) He has become physically dependent on famotidine
ANSWER: A
Rationale:
Loss of effect after 1 to 2 weeks of continuous H2 receptor antagonist use, with good adherence and a stable dose, is the classic picture of tachyphylaxis: hypergastrinemia-driven ECL cell growth and H2 receptor upregulation progressively overcome the reversible, competitive blockade. Because this tolerance limits H2 receptor antagonists for long-term maintenance, the appropriate step is to switch to a proton pump inhibitor, which binds the pump irreversibly and sustains suppression.
Option B: Option B is incorrect: the scenario specifies good adherence, and the time course points to tolerance, not non-adherence.
Option C: Option C is incorrect: the effect is physiologic tolerance, not drug degradation.
Option D: Option D is incorrect: escalating the dose is not the recommended strategy and does not address the underlying adaptive mechanism.
Option E: Option E is incorrect: this is pharmacodynamic tolerance, not physical dependence.
9. A 38-year-old woman reports persistent reflux despite taking her once-daily proton pump inhibitor. On questioning, she takes it at bedtime, well after her evening meal, because she finds that convenient. Adherence is otherwise excellent. What single change is most likely to improve her control?
A) Switch her to an antacid because the proton pump inhibitor has failed
B) Add a second proton pump inhibitor brand to the bedtime dose
C) Tell her timing does not matter and look for another diagnosis
D) Increase the dose while keeping the bedtime, empty-stomach timing
E) Have her take the proton pump inhibitor 30 to 60 minutes before breakfast, because the drug can only inactivate actively secreting pumps, and pre-meal dosing aligns peak drug levels with the meal-stimulated surge in pump activity
ANSWER: E
Rationale:
The problem is timing, not drug failure. A proton pump inhibitor inactivates only pumps that are actively secreting, and taking it on an empty stomach at bedtime exposes it to few active pumps. Taking it 30 to 60 minutes before the first meal aligns peak plasma levels with the meal-driven surge in parietal cell activity, maximizing the fraction of pumps inhibited. Correcting this common error often restores control without any change in drug or dose.
Option A: Option A is incorrect: the agent has not failed; it is being mistimed.
Option B: Option B is incorrect: adding a second product at the wrong time does not fix the timing problem.
Option C: Option C is incorrect: timing relative to meals is precisely what matters for proton pump inhibitors.
Option D: Option D is incorrect: raising the dose while keeping the ineffective bedtime, empty-stomach timing does not address the mechanism.
10. A 67-year-old man taking cimetidine for several months develops breast tenderness and enlargement, and his serum creatinine has risen modestly. His estimated GFR (glomerular filtration rate) by other measures appears stable and he has no signs of true renal injury. What is the best explanation and management?
A) Cimetidine has caused acute kidney injury, so it should be continued while nephrology is consulted
B) The gynecomastia is unrelated to cimetidine and the creatinine rise reflects true renal decline
C) Cimetidine blocks androgen receptors (causing gynecomastia) and inhibits renal tubular secretion of creatinine (raising serum creatinine without lowering the actual GFR); switch to famotidine, which has neither effect while providing equivalent acid suppression
D) The findings indicate prostate disease and are unrelated to the drug
E) He should increase the cimetidine dose to better control symptoms
ANSWER: C
Rationale:
Both findings are explained by cimetidine. At higher doses it blocks androgen receptors, producing gynecomastia and sexual dysfunction in men, and it inhibits the renal tubular secretion of creatinine, which raises serum creatinine even though glomerular filtration is unchanged. The clean solution is to switch to famotidine, which lacks both the anti-androgenic effect and meaningful interference with creatinine handling while giving equivalent acid suppression.
Option A: Option A is incorrect: this is not acute kidney injury; the GFR is unchanged, so continuing cimetidine is not appropriate.
Option B: Option B is incorrect: both the gynecomastia and the creatinine rise are well-recognized cimetidine effects, not unrelated findings.
Option D: Option D is incorrect: the combination of gynecomastia and an isolated creatinine rise points to cimetidine, not prostate disease.
Option E: Option E is incorrect: increasing the dose would intensify the very effects causing his problems.
11. A 52-year-old man with HIV is maintained on an antiretroviral regimen containing atazanavir, a drug whose absorption is strongly dependent on an acidic gastric environment for dissolution. He is started on a proton pump inhibitor for reflux, and his subsequent atazanavir levels and virologic control worsen. What is the most likely explanation?
A) The proton pump inhibitor raised intragastric pH, impairing the acid-dependent dissolution and absorption of atazanavir and thereby lowering its plasma levels
B) The proton pump inhibitor chemically inactivated atazanavir in the bloodstream
C) The proton pump inhibitor induced atazanavir metabolism by the proton pump
D) Atazanavir blocked the proton pump inhibitor's activation, indirectly lowering its own level
E) The interaction reflects the proton pump inhibitor competing with atazanavir for renal excretion
ANSWER: A
Rationale:
Atazanavir requires an acidic stomach for adequate dissolution and absorption. By raising intragastric pH, a proton pump inhibitor reduces atazanavir dissolution, lowering its absorption and plasma concentrations and undermining virologic control — a clinically important pH-dependent absorption interaction.
Option B: Option B is incorrect: the proton pump inhibitor does not chemically inactivate atazanavir in the blood; the effect is reduced gastrointestinal absorption.
Option C: Option C is incorrect: the proton pump does not metabolize atazanavir, and proton pump inhibitors do not induce its metabolism by such a mechanism.
Option D: Option D is incorrect: the relevant effect is the proton pump inhibitor reducing atazanavir absorption via pH, not atazanavir lowering its own level by blocking proton pump inhibitor activation.
Option E: Option E is incorrect: the mechanism is impaired pH-dependent absorption, not competition for renal excretion.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.